Does Medicaid Cover Ozempic? The State-by-State Reality

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

As of May 2026. Confirm directly with your state Medicaid program. Coverage varies by state, by MCO, and by time. Always confirm with your specific plan administrator.

Key Takeaways

• Every state Medicaid program covers Ozempic for type 2 diabetes. PA is standard. Step therapy is common, often requiring metformin and sometimes a sulfonylurea or another lower-cost diabetes drug first
• Ozempic is not FDA-approved for weight loss. No state Medicaid program covers Ozempic for weight loss as a labeled indication
• Wegovy and Saxenda weight-loss coverage varies sharply by state. Roughly 14 state Medicaid programs cover GLP-1 medications for obesity as of May 2026
• Medicaid is administered by states, often through managed care organizations. PA criteria, step therapy, and quantity limits vary by state and by MCO within a state
• Medicaid Fair Hearings are the appeal path. Decisions are binding on the state Medicaid agency

Direct answer

State Medicaid programs cover Ozempic for adults with type 2 diabetes through a prior authorization process. The exact PA criteria and step therapy vary widely by state and by managed care organization within a state. As of May 2026, no state Medicaid program covers Ozempic for weight loss because Ozempic is not FDA-approved for that indication. Wegovy and Saxenda weight-loss coverage exists in some states but not others. Patients should consult their state Medicaid pharmacy bulletin or their MCO's drug list for specifics.

Table of contents

1. How Medicaid drug coverage works: federal floor, state choices
2. The role of Medicaid managed care organizations
3. Type 2 diabetes coverage: the broadly available baseline
4. Weight-loss coverage: where Medicaid splits
5. State examples: California, Texas, Florida, New York, Michigan
6. Step therapy in Medicaid: what to expect
7. The Medicaid Fair Hearing appeal path
8. Medicaid copays and the federal limits
9. Dual-eligible beneficiaries (Medicare and Medicaid)
10. When state Medicaid denies: alternatives including 503A compounded
11. Contrary view: why Medicaid is conservative on GLP-1 weight loss
12. Decision framework
13. FAQ
14. Sources

How Medicaid drug coverage works: federal floor, state choices

Medicaid is a joint federal-state program. The federal government, through CMS, sets baseline requirements and provides matching funds. States administer the program and set additional rules.

For prescription drugs, the federal Medicaid Drug Rebate Program requires participating manufacturers to give Medicaid the lowest negotiated price they offer to commercial buyers. In exchange, Medicaid agrees to cover the manufacturer's drugs that meet medical necessity. States set their own preferred drug lists, PA criteria, and step therapy within this framework.

The federal weight-loss exclusion that applies to Medicare Part D does not apply to Medicaid. States may choose to cover weight-loss drugs. They may also choose to exclude or restrict them. The choice belongs to the state.

The role of Medicaid managed care organizations

Most Medicaid enrollees today are in managed care organizations that administer the benefit on a capitated basis. Major Medicaid MCOs include Centene, Molina Healthcare, UnitedHealthcare Community Plan, Anthem Medicaid plans, Aetna Better Health, and state-specific MCOs.

The MCO operates within the state Medicaid framework but can set its own PA criteria, formulary, and step therapy within state-approved bounds. In a state with multiple Medicaid MCOs, two enrollees with the same diagnosis can face different coverage rules if they are enrolled in different MCOs.

Some state Medicaid programs use a single uniform PDL across all MCOs. Others allow MCO-specific formularies. The variation matters for Ozempic coverage; the state pharmacy bulletin and the specific MCO drug list both apply.

Type 2 diabetes coverage: the broadly available baseline

Every state Medicaid program covers Ozempic for T2D, generally with PA. The PA criteria are predictable in shape:

• Documented type 2 diabetes (ICD-10 E11.x)
• Age 18 or older
• Prior trial of metformin or documented contraindication
• Often: prior trial of a sulfonylurea or another lower-cost agent
• Recent A1c value

The fine print varies. Some states allow direct approval if the prescriber attests to certain criteria; others require chart documentation. Some states cap initial approvals at 6 months; others approve for 12 months.

Weight-loss coverage: where Medicaid splits

The federal Medicaid framework allows states to cover weight-loss drugs. State choices have produced a patchwork. As of May 2026, approximately 14 state Medicaid programs cover one or more GLP-1 medications for obesity, with the rest excluding or restricting coverage for that indication. The list shifts as states make budget and policy decisions.

Common patterns:

• States that cover Wegovy for obesity: Massachusetts, Minnesota, California (in some MCOs), Pennsylvania, and others. Coverage typically requires BMI 30+ or BMI 27+ with comorbidity, plus PA.
• States that exclude weight-loss drug coverage: Texas, Florida, Tennessee, and several others as of May 2026. Some of these states cover Wegovy under the November 2024 CMS rule for the cardiovascular indication only, not for obesity.
• States that have shifted recently: Coverage decisions are budget-sensitive. State Medicaid programs that have added or removed GLP-1 obesity coverage in 2024 to 2026 reflect state budget pressures and changing clinical evidence.

The right source of truth is the state Medicaid pharmacy bulletin or the MCO drug list for the specific year. National summaries become outdated quickly.

State examples: California, Texas, Florida, New York, Michigan

California (Medi-Cal): Covers Ozempic for T2D with PA through the Medi-Cal Rx program (the carve-out pharmacy benefit administered by Magellan). Step therapy with metformin required. Wegovy coverage for obesity is available with strict BMI and documentation requirements.

Texas Medicaid: Covers Ozempic for T2D with PA. Wegovy and Saxenda weight-loss coverage is not generally available. Texas Medicaid is heavily MCO-administered (Superior, Amerigroup, Molina, others); specifics vary by MCO.

Florida Medicaid: Covers Ozempic for T2D with PA. Weight-loss drug coverage is restricted. PA criteria include documented metformin trial and recent A1c.

New York Medicaid: Covers Ozempic for T2D with PA. Wegovy coverage is available for obesity under specific BMI and PA criteria. The state has expanded GLP-1 access in recent years.

Michigan Medicaid: Covers Ozempic for T2D with PA. Wegovy coverage for obesity is available under PA.

These descriptions are summaries. The state pharmacy bulletin and MCO drug list are authoritative.

Step therapy in Medicaid: what to expect

Step therapy in Medicaid is common because state budgets favor lower-cost drugs first. For Ozempic, step therapy typically requires:

• Metformin trial at maximum tolerated dose
• Sometimes a sulfonylurea trial
• Sometimes a trial of a preferred GLP-1 (some states prefer Trulicity or Bydureon BCise)

Step-therapy exceptions are available with documented clinical reasoning. The exception request typically requires the prescriber to attest to a specific clinical reason why the preferred step is not appropriate.

The Medicaid Fair Hearing appeal path

Medicaid beneficiaries have a federal right to a Fair Hearing when a benefit is denied, reduced, or terminated. The Fair Hearing is conducted by an administrative law judge or hearing officer with the state Medicaid agency.

The process:

1. The denial notice from the MCO or state Medicaid agency includes the Fair Hearing request form and deadline (typically 60 to 90 days)
2. You request the hearing in writing or by phone
3. The MCO or state must continue the benefit pending the hearing if you request it within the timely-filing window (typically 10 days from the notice)
4. The hearing is held by phone or in person within 90 days
5. You present evidence: medical records, prescriber letter, plan policy
6. The decision arrives in writing, typically within 30 days of the hearing

If the Fair Hearing decision is unfavorable, judicial review in state court may be available. Practical experience: many MCO denials reverse before the hearing once the state Medicaid agency reviews the file.

Medicaid copays and the federal limits

Federal Medicaid rules limit copays. Most state Medicaid programs charge $0 to $8 per prescription for adults. Some states charge no copay at all. Children, pregnant women, and people in long-term care facilities are generally exempt from drug copays.

Federal law prohibits Medicaid pharmacies from withholding a medically necessary drug if the patient cannot pay the copay at the counter. The pharmacy must dispense the drug and bill the patient for the copay later.

Dual-eligible beneficiaries (Medicare and Medicaid)

Dual-eligible beneficiaries have both Medicare and Medicaid. For prescription drugs, Medicare Part D is the primary payer; Medicaid wraps around for Part D-excluded drugs and for cost-sharing reductions.

For Ozempic, dual-eligibles typically receive coverage through Part D for T2D. They are also typically full Low-Income Subsidy recipients, which reduces copays to roughly $11.20 per brand fill in 2026.

For weight-loss drugs, dual-eligibles face the Part D exclusion. State Medicaid may or may not cover the weight-loss drug as a wrap-around benefit. The specifics vary by state.

When state Medicaid denies: alternatives including 503A compounded

If state Medicaid denies Ozempic coverage through PA and Fair Hearing, the brand-name alternatives narrow. The Novo Nordisk patient assistance program may apply for income-qualified patients. For most Medicaid beneficiaries, the PAP income threshold (approximately 400% of FPL) is far above Medicaid eligibility income, so PAP eligibility is generally easier than for some commercial enrollees.

503A compounded semaglutide via telehealth is a cash-pay alternative. The product is not FDA-approved, is not equivalent to brand-name Ozempic, and is not billable to Medicaid. For Medicaid beneficiaries who cannot afford even cash-pay compounded medication, the brand-name PAP is usually the better path.

FormBlends works with state-licensed 503A pharmacies and licensed clinicians for clinically eligible patients. For Medicaid-eligible patients with T2D, the strong recommendation is to exhaust the Medicaid coverage path first, including Fair Hearing if needed.

Contrary view: why Medicaid is conservative on GLP-1 weight loss

State Medicaid programs face budget constraints that commercial insurers do not. Medicaid spending grows in step with enrollment and per-enrollee cost. Adding broad GLP-1 weight-loss coverage to a state Medicaid budget creates a meaningful new expenditure that state legislatures have to fund.

The case for conservative coverage: limited dollars, competing health priorities, and uncertainty about long-term outcomes in real-world Medicaid populations who may have less consistent follow-up than clinical trial participants.

The case for broader coverage: obesity-related Medicaid costs (cardiovascular disease, kidney disease, complications of diabetes) are real. Investment in weight-loss medication today can reduce downstream Medicaid spending. The evidence base, while not yet long-term, is strong.

States are making the call in different directions, and the calls are shifting. The patchwork reflects ongoing policy reckoning, not a settled answer.

Decision framework

If you have T2D and Medicaid coverage: file the PA. Coverage is generally available across states. Build the file with metformin trial documentation and recent A1c.

If you want Ozempic for weight loss on Medicaid: Ozempic is not the right ask (FDA labeling). Ask whether your state Medicaid covers Wegovy or Saxenda for obesity. If yes, the path is PA for the labeled obesity drug.

If your state Medicaid does not cover weight-loss drugs: internal appeal and Fair Hearing will not overturn the state policy. PAP for the brand-name drug or 503A compounded are the realistic alternatives.

If you are dual-eligible: Part D rules apply for the primary payment. State Medicaid wrap-around may help with cost-sharing or with non-Part D drugs.

FAQ

Does Medicaid cover Ozempic? For T2D yes, in every state with PA. For weight loss no, because Ozempic is not FDA-approved for it.

Why does coverage vary? Medicaid is state-administered. Each state sets its own rules within the federal floor.

Which states cover GLP-1 for weight loss? Roughly 14 states cover Wegovy or Saxenda for obesity as of May 2026. The list shifts.

What's the PA criteria? T2D, age 18+, metformin trial, often step therapy with a sulfonylurea or preferred GLP-1.

How do I appeal a denial? Medicaid Fair Hearing, federally protected. Request within 60 to 90 days of the notice.

What's the copay? Most state Medicaid programs charge $0 to $8 per prescription.

What about dual-eligibles? Part D primary, Medicaid wrap-around for excluded drugs and cost-sharing reductions.

Sources

1. Centers for Medicare and Medicaid Services. Medicaid Drug Rebate Program. 2026.
2. State Medicaid pharmacy bulletins (California Medi-Cal Rx, Texas, Florida, New York, Michigan). 2026.
3. Kaiser Family Foundation. State Medicaid coverage of GLP-1 medications for weight loss. 2026 update.
4. Centers for Medicare and Medicaid Services. Medicaid managed care rules.
5. U.S. Food and Drug Administration. Ozempic prescribing information.
6. U.S. Food and Drug Administration. Wegovy prescribing information including SELECT CV indication.
7. Marso SP, et al. SUSTAIN-6 cardiovascular outcomes. NEJM. 2016;375:1834-1844.
8. Lincoff AM, et al. SELECT cardiovascular outcomes in obesity. NEJM. 2023;389:2221-2232.
9. Centers for Medicare and Medicaid Services. Final rule on GLP-1 for cardiovascular indications. November 2024.
10. American Diabetes Association. Standards of Care 2026.
11. U.S. Food and Drug Administration. 503A compounding regulations.
12. 42 CFR 431.200 et seq. Medicaid Fair Hearing rights and procedures.

Footer disclaimers

Platform Disclaimer. FormBlends provides telehealth services through licensed clinicians. We do not enroll beneficiaries in Medicaid or adjudicate Medicaid claims. State Medicaid policies vary widely and change over time. Information here reflects publicly available materials as of May 2026.

Compounded Medication Notice. Compounded semaglutide is produced by a state-licensed 503A pharmacy for an individual patient based on a prescription. It is not FDA-approved, is not equivalent to brand-name Ozempic, and is not billable to Medicaid. Clinical decisions belong with a prescriber.

Results Disclaimer. Coverage results depend on state Medicaid policy, MCO rules, and individual clinical documentation. Examples here do not predict outcomes for any specific case.

Trademark Notice. Ozempic, Wegovy, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. Bydureon is a registered trademark of AstraZeneca. Medicaid is a joint federal-state program. FormBlends is independent.